Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 14, 2014 - Issue 1
Submit an article Journal homepage
271
Views
18
CrossRef citations to date
0
Altmetric
Perspective

Vitamin D and multiple sclerosis: where do we go from here?

Jonatan SalzerDepartment of Pharmacology and Clinical Neuroscience, Section of Neurology, Umeå University, SE-90187, Umeå, SwedenCorrespondence[email protected]
,
Martin BiströmDepartment of Pharmacology and Clinical Neuroscience, Section of Neurology, Umeå University, SE-90187, Umeå, Sweden
&
Peter SundströmDepartment of Pharmacology and Clinical Neuroscience, Section of Neurology, Umeå University, SE-90187, Umeå, Sweden
Pages 9-18 | Published online: 09 Dec 2013

References

  • Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N. Engl. J. Med. 343(13), 938–952 (2000).
  • Ascherio A, Munger KL, Lunemann JD. The initiation and prevention of multiple sclerosis. Nat. Rev. Neurol. 8(11), 602–612 (2012).
  • Sawcer S, Hellenthal G, Pirinen M et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476(7359), 214–219 (2011).
  • Beecham AH, Patsopoulos NA, Xifara DK et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat. Genet. 45, 1353–1360 (2013).
  • Sundstrom P, Salzer J. Vitamin D and multiple sclerosis: timing of sampling, treatment and prevention. Biomark. Med. 7(2), 193–195 (2013).
  • Handel AE, Giovannoni G, Ebers GC, Ramagopalan SV. Environmental factors and their timing in adult-onset multiple sclerosis. Nat. Rev. Neurol. 6(3), 156–166 (2010).
  • Holick MF. Vitamin D deficiency. N. Engl. J. Med. 357(3), 266–281 (2007).
  • Thompson PD, Jurutka PW, Haussler CA, Whitfield GK, Haussler MR. Heterodimeric DNA binding by the vitamin D receptor and retinoid X receptors is enhanced by 1,25-dihydroxyvitamin D3 and inhibited by 9-cis-retinoic acid. Evidence for allosteric receptor interactions. J. Biol. Chem. 273(14), 8483–8491 (1998).
  • Jimenez-Lara AM, Aranda A. Interaction of vitamin D and retinoid receptors on regulation of gene expression. Horm. Res. 54(5–6), 301–305 (2000).
  • Mora JR, Iwata M, Von Andrian UH. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat. Rev. Immunol. 8(9), 685–698 (2008).
  • Reid IR, Bolland MJ, Grey A. Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet doi:10.1016/S0140–6736(13)61647–5 (2013) ( Epub ahead of print).
  • Salzer J, Hallmans G, Nystrom M, Stenlund H, Wadell G, Sundstrom P. Vitamin D as a protective factor in multiple sclerosis. Neurology 79(21), 2140–2145 (2012).
  • Salzer J, Hallmans G, Nystrom M, Stenlund H, Wadell G, Sundstrom P. Vitamin A and systemic inflammation as protective factors in multiple sclerosis. Mult. Scler. 19(8), 1046–1051 (2013).
  • Hart PH, Gorman S, Finlay-Jones JJ. Modulation of the immune system by UV radiation: more than just the effects of vitamin D? Nat. Rev. Immunol. 11(9), 584–596 (2011).
  • Smolders J, Damoiseaux J, Menheere P, Hupperts R. Vitamin D as an immune modulator in multiple sclerosis, a review. J. Neuroimmunol. 194(1–2), 7–17 (2008).
  • Shaw NJ, Mughal MZ. Vitamin D and child health part 1 (skeletal aspects). Arch. Dis. Child. 98(5), 363–367 (2013).
  • Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296(23), 2832–2838 (2006).
  • Simpson S Jr, Taylor B, Blizzard L et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann. Neurol. 68(2), 193–203 (2010).
  • IOM (Institute of Medicine). Dietary Reference Intakes for Calcium and Vitamin D. The National Academies Press, Washington DC, USA (2011).
  • Holick MF, Binkley NC, Bischoff-Ferrari HA et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96(7), 1911–1930 (2011).
  • Brannon PM, Yetley EA, Bailey RL, Picciano MF. Overview of the conference “Vitamin D and Health in the 21st Century: an Update”. Am. J. Clin. Nutr. 88(2), 483S–490S (2008).
  • Saltyte Benth J, Myhr KM, Loken-Amsrud KI et al. Modelling and prediction of 25-hydroxyvitamin D levels in Norwegian relapsing-remitting multiple sclerosis patients. Neuroepidemiology 39(2), 84–93 (2012).
  • Grant WB. Critique of the U-shaped serum 25-hydroxyvitamin D level-disease response relation. Dermatoendocrinol. 1(6), 289–293 (2009).
  • Tuohimaa P, Tenkanen L, Ahonen M et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int. J. Cancer 108(1), 104–108 (2004).
  • Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch. Intern. Med. 168(15), 1629–1637 (2008).
  • Wang TJ, Pencina MJ, Booth SL et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 117(4), 503–511 (2008).
  • Durup D, Jorgensen HL, Christensen J, Schwarz P, Heegaard AM, Lind B. A reverse J-shaped association of all-cause mortality with serum 25-hydroxyvitamin D in general practice: the CopD study. J. Clin. Endocrinol. Metab. 97(8), 2644–2652 (2012).
  • Michaelsson K, Baron JA, Snellman G et al. Plasma vitamin D and mortality in older men: a community-based prospective cohort study. Am. J. Clin. Nutr. 92(4), 841–848 (2010).
  • Jenab M, Bueno-De-Mesquita HB, Ferrari P et al. Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations:a nested case-control study. BMJ 340, b5500 (2010)
  • Brondum-Jacobsen P, Nordestgaard BG, Schnohr P, Benn M. 25-Hydroxyvitamin D and symptomatic ischemic stroke: an original study and meta-analysis. Ann. Neurol. 73(1), 38–47 (2013).
  • Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J. Clin. Endocrinol. Metab. 67(2), 373–378 (1988).
  • Manson JE, Bassuk SS, Lee IM et al. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp. Clin. Trials 33(1), 159–171 (2012).
  • Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 9(5), 520–532 (2011).
  • Sloka S, Silva C, Pryse-Phillips W, Patten S, Metz L, Yong VW. A quantitative analysis of suspected environmental causes of MS. Can. J. Neurol. Sci. 38(1), 98–105 (2011).
  • Gale CR, Martyn CN. Migrant studies in multiple sclerosis. Prog. Neurobiol. 47(4–5), 425–448 (1995).
  • Lucas RM, Ponsonby AL, Dear K et al. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology 76(6), 540–548 (2011).
  • Ascherio A, Munger KL, Giovannucci E. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology 77(14), 1405, author reply 1405–1406 (2011).
  • Vimaleswaran KS, Berry DJ, Lu C et al. Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts. PLoS Med. 10(2), e1001383 (2013).
  • Brot C, Jorgensen NR, Sorensen OH. The influence of smoking on vitamin D status and calcium metabolism. Eur. J. Clin. Nutr. 53(12), 920–926 (1999).
  • Hedstrom AK, Olsson T, Alfredsson L. High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women. Mult. Scler. 18(9), 1334–1336 (2012).
  • Salzer J, Hallmans G, Nystrom M, Stenlund H, Wadell G, Sundstrom P. Smoking as a risk factor for multiple sclerosis. Mult. Scler. 19(8), 1022–1027 (2013).
  • Schwarz A, Navid F, Sparwasser T, Clausen BE, Schwarz T. 1,25-dihydroxyvitamin D exerts similar immunosuppressive effects as UVR but is dispensable for local UVR-induced immunosuppression. J. Invest. Dermatol. 132(12), 2762–2769 (2012).
  • Mcloone P, Simics E, Barton A, Norval M, Gibbs NK. An action spectrum for the production of cis-urocanic acid in human skin in vivo. J. Invest. Dermatol. 124(5), 1071–1074 (2005).
  • Kammeyer A, Pavel S, Asghar SS, Bos JD, Teunissen MB. Prolonged increase of cis-urocanic acid levels in human skin and urine after single total-body ultraviolet exposures. Photochem. Photobiol. 65(3), 593–598 (1997).
  • Moodycliffe AM, Norval M, Kimber I, Simpson TJ. Characterization of a monoclonal antibody to cis-urocanic acid: detection of cis-urocanic acid in the serum of irradiated mice by immunoassay. Immunology 79(4), 667–672 (1993).
  • Correale J, Farez MF. Modulation of multiple sclerosis by sunlight exposure: Role of cis-urocanic acid. J. Neuroimmunol 261(1–2), 134–140 (2013).
  • Holmoy T, Moen SM, Gundersen TA et al. 25-hydroxyvitamin D in cerebrospinal fluid during relapse and remission of multiple sclerosis. Mult. Scler. 15(11), 1280–1285 (2009).
  • Ramagopalan SV, Dyment DA, Cader MZ et al. Rare variants in the CYP27B1 gene are associated with multiple sclerosis. Ann. Neurol. 70(6), 881–886 (2011).
  • Barizzone N, Pauwels I, Luciano B et al. No evidence for a role of rare CYP27B1 functional variations in multiple sclerosis. Ann. Neurol. 73(3), 433–437 (2013).
  • Reinthaler E, Machetanz G, Hotzy C et al. No evidence for a role of rare CYP27B1 variants in Austrian multiple sclerosis patients. Mult. Scler. doi:10.1177/1352458513498130 (2013) ( Epub ahead of print).
  • Ban M, Caillier S, Mero IL et al. No evidence of association between mutant alleles of the CYP27B1 gene and multiple sclerosis. Ann. Neurol. 73(3), 430–432 (2013).
  • Wang TJ, Zhang F, Richards JB et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 376(9736), 180–188 (2010).
  • Ahn J, Yu K, Stolzenberg-Solomon R et al. Genome-wide association study of circulating vitamin D levels. Hum. Mol. Genet. 19(13), 2739–2745 (2010).
  • Disanto G, Sandve GK, Berlanga-Taylor AJ et al. Vitamin D receptor binding, chromatin states and association with multiple sclerosis. Hum. Mol. Genet. 21(16), 3575–3586 (2012).
  • Ramagopalan SV, Maugeri NJ, Handunnetthi L et al. Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet. 5(2), e1000369 (2009).
  • Smith GD, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int. J. Epidemiol. 32(1), 1–22 (2003).
  • Munger KL, Zhang SM, O’reilly E et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 62(1), 60–65 (2004).
  • Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 358(9292), 1500–1503 (2001).
  • Tremlett H, Van Der Mei IA, Pittas F et al. Monthly ambient sunlight, infections and relapse rates in multiple sclerosis. Neuroepidemiology 31(4), 271–279 (2008).
  • Mowry EM, Waubant E, Mcculloch CE et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann. Neurol. 72(2), 234–240 (2012).
  • Mosayebi G, Ghazavi A, Ghasami K, Jand Y, Kokhaei P. Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunol. Invest. 40(6), 627–639 (2011).
  • Stein MS, Liu Y, Gray OM et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology 77(17), 1611–1618 (2011).
  • Kampman MT, Steffensen LH, Mellgren SI, Jorgensen L. Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Mult. Scler. 18(8), 1144–1151 (2012).
  • Soilu-Hanninen M, Aivo J, Lindstrom BM et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 83(5), 565–571 (2012).
  • Shaygannejad V, Janghorbani M, Ashtari F, Dehghan H. Effects of adjunct low-dose vitamin d on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Mult. Scler. Int. 2012, 452541 (2012).
  • Pozuelo-Moyano B, Benito-Leon J, Mitchell AJ, Hernandez-Gallego J. A systematic review of randomized, double-blind, placebo-controlled trials examining the clinical efficacy of vitamin D in multiple sclerosis. Neuroepidemiology 40(3), 147–153 (2012).
  • Smolders J, Hupperts R, Barkhof F et al. Efficacy of vitamin D(3) as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. J. Neurol. Sci. 311(1–2), 44–49 (2011).
  • Dorr J, Ohlraun S, Skarabis H, Paul F. Efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial. Trials 13, 15 (2012).
  • O Connel K, Kelly S, Kinsella K et al. Dose-related effects of vitamin D on immune responses in patients with clinically isolated syndrome and healthy control participants: study protocol for an exploratory randomized double-blind placebo-controlled trial. Trials 14(1), 272 (2013).
  • Vukusic S, Hutchinson M, Hours M et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 127(Pt 6), 1353–1360 (2004).
  • Ghezzi A, Annovazzi P, Portaccio E, Cesari E, Amato MP. Current recommendations for multiple sclerosis treatment in pregnancy and puerperium. Expert Rev. Clin. Immunol. 9(7), 683–692 (2013).
  • Manaseki-Holland S, Maroof Z, Bruce J et al. Effect on the incidence of pneumonia of vitamin D supplementation by quarterly bolus dose to infants in Kabul: a randomised controlled superiority trial. Lancet 379(9824), 1419–1427 (2012).
  • Murdoch DR, Slow S, Chambers ST et al. Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial. JAMA 308(13), 1333–1339 (2012).
  • Mcalindon T, Lavalley M, Schneider E et al. Effect of vitamin D supplementation on progression of knee pain and cartilage volume loss in patients with symptomatic osteoarthritis: a randomized controlled trial. JAMA 309(2), 155–162 (2013).
  • Witham MD, Price RJ, Struthers AD et al. Cholecalciferol treatment to reduce blood pressure in older patients with isolated systolic hypertension: the vitdish randomized controlled trial. JAMA Intern. Med. doi:10.1001/jamainternmed.2013.9043 (2013) ( Epub ahead of print).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.